ZHONGZHIPHARM(03737) issues a profit warning, expecting a decrease in annual net profit of no less than 70%.
Zhongzhi Pharmaceutical (03737) announced that it expects the annual net profit for the year ending December 31, 2025, to decrease by no less than 70% compared to the year ending December 31, 2024. In 2025, due to industry policy adjustments leading to a temporary decline in sales revenue and profit being affected to some extent, the Group will maintain its market investment efforts and actively explore new business growth opportunities.
ZHONGZHIPHARM (03737) announced that it is expected that the net profit for the full year ending December 31, 2025 will decline by no less than 70% compared to the full year ending December 31, 2024. In 2025, due to industry policy adjustments leading to a short-term decrease in sales revenue, profits will be somewhat affected. The Group will continue to maintain market investment efforts and actively explore new business growth opportunities.
Related Articles

FUTURE DATA (08229) issues 5.4 million share options.

GENSCRIPT BIO (01548): Meng Jiangge appointed as a director of Legend Biotech

CHINA SANDI (00910) issues a profit warning, expecting a loss of 4.403 billion yuan in 2024.
FUTURE DATA (08229) issues 5.4 million share options.

GENSCRIPT BIO (01548): Meng Jiangge appointed as a director of Legend Biotech

CHINA SANDI (00910) issues a profit warning, expecting a loss of 4.403 billion yuan in 2024.

RECOMMEND

Paul Chan Says Hong Kong Has Licensed 11 Virtual Asset Exchanges, Stablecoin Licenses Expected Later This Year
22/01/2026

Ministry Of Finance And Other Departments Introduce Comprehensive Fiscal And Financial Policies To Boost Domestic Demand
22/01/2026

Capital Migration: Five Years On, An In‑Depth Analysis Of China’s 11 High‑Growth Venture Capital Tracks In 2025
22/01/2026


